Quick Answer
Foghorn Therapeutics Inc. reported Net Income Loss of -$74.28 million for the year ending 2025.
- Foghorn Therapeutics Inc. showed an increase of +14.2% in Net Income Loss from 2024 to 2025.
- This data is from Foghorn Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$13.09 million | Q1 2020: -$13.95 million | Q2 2020: -$15.72 million | Q3 2020: -$18.37 million | Q1 2021: -$22.99 million | Q2 2021: -$23.11 million | Q3 2021: -$26.08 million | Q1 2022: -$26.91 million | Q2 2022: -$27.31 million | Q3 2022: -$25.77 million | Q1 2023: -$30.49 million | Q2 2023: -$29.49 million | Q3 2023: -$14.35 million | Q1 2024: -$25.02 million | Q2 2024: -$22.98 million | Q3 2024: -$19.12 million | Q1 2025: -$18.83 million | Q2 2025: -$17.94 million | Q3 2025: -$15.85 million.
- Over the full 7 years of available data (2019 to 2025), Foghorn Therapeutics Inc.'s Net Income Loss has declined by 45.3%.
- Historical annual values: Fiscal year 2025: -$74.28 million | Fiscal year 2024: -$86.62 million | Fiscal year 2023: -$98.43 million | Fiscal year 2022: -$108.88 million | Fiscal year 2021: -$101.32 million | Fiscal year 2020: -$68.80 million | Fiscal year 2019: -$51.13 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: